Key result
Levosimendan added to dobutamine improves outcomes in ADHF refractory to dobutamine alone.
Why the study?
Does levosimendan added to dobutamine improve outcomes in patients with acute decompensated heart failure refractory to dobutamine alone?
Does levosimendan added to dobutamine improve outcomes in patients with acute decompensated heart failure refractory to dobutamine alone?
Levosimendan added to dobutamine may improve outcomes in acute decompensated heart failure refractory to dobutamine alone.
Hypothesis-generating in refractory ADHF; requires confirmation in larger trials before practice change.
= 0.01). In conclusion, levosimendan added to dobutamine may improve the outcome of ADHF refractory to dobutamine alone.
No takes yet. Share an insight, caveat, or question.
Juguet et al. (2020) studied this question. Levosimendan added to dobutamine improved outcomes in patients with acute decompensated heart failure refractory to dobutamine alone (p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: